The inhibitory effects of recombinant human erythropoietin (rhEPO) were examined against (1) the progression of renal fibrosis in mice with complete unilateral ureteral obstruction and (2) the TGF-␤1-induced epithelial-to-mesenchymal transition (EMT) in MDCK cells. Unilateral ureteral obstruction was induced in BALB/c mice and rhEPO (100 or 1000 U/kg, intraperitoneally, every other day) or vehicle was administered from day 3 to day 14. Immunoblotting and immunohistochemistry revealed increased expressions of TGF-␤1, ␣-smooth muscle actin (␣-SMA), and fibronectin and decreased expression of E-cadherin in the obstructed kidneys. In contrast, rhEPO treatment significantly attenuated the upregulation of TGF-␤1 and ␣-SMA and the downregulation of E-cadherin. MDCK cells were treated with TGF-␤1 (5 ng/ml) for 48 h to induce EMT, and the cells were then co-treated with TGF-␤1 and rhEPO for another 48 h. Increased expressions of ␣-SMA and vimentin and decreased expressions of zona occludens-1 and E-cadherin were observed after TGF-␤1 treatment, and these changes were markedly attenuated by rhEPO co-treatment. TGF-␤1 increased phosphorylated Smad-2 expression in MDCK cells, which was decreased by rhEPO co-treatment. In conclusion, rhEPO treatment inhibits the progression of renal fibrosis in obstructed kidney and attenuates the TGF-␤1-induced EMT. It is suggested that the renoprotective effects of rhEPO could be mediated, at least partly, by inhibition of TGF-␤1-induced EMT.
C hronic renal failure is characterized by its irreversibility where progressive renal fibrosis is commonly observed regardless of the cause of the diseases. One of the main effector cells that contribute to the development of progressive renal fibrosis in chronic renal diseases is the tubulointerstitial fibroblast. Importantly, a large proportion of the interstitial fibroblasts are known to be originated from the tubular epithelial cells through the process of epithelial-tomesenchymal transition (EMT) in the progression to the renal fibrosis (1, 2) . During the process of EMT, tubular epithelial cells lose their epithelial phenotype but acquire the mesenchymal phenotype and the tubular basement membranes are disrupted (3, 4) . Consequently, this process induces renal tubular destruction and accumulation of myofibroblasts, and TGF-␤1 is proposed to be the major regulator for inducing EMT (5) . In contrast to the major role of EMT in contributing to the disease progression, several studies have suggested that EMT of the tubular epithelial cell could be reversible (6 -8) . Therefore, from the clinical point of view, it is important to study which intervention or drug therapy could potentially reverse or inhibit the EMT in the kidney and, hence, retard disease progression to chronic renal disease.
Recombinant human erythropoietin (rhEPO) has been demonstrated to play an important role as a novel cytoprotective agent in addition to the hematopoietic effects (9 -11) . For example, rhEPO has multiple paracrine and autocrine functions that coordinate the local responses to injury by attenuating both the primary (apoptotic) and the secondary (inflammatory) causes of cell death (11) . Consistent with this finding, rhEPO treatment in rats with cisplatin-induced (12, 13) or ischemia-and reperfusion-induced (14) acute renal failure enhances their functional recovery. Moreover, in contrast to the concerns about the rhEPO treatment-associated potential deterioration of renal function (15) , clinical studies have reported that rhEPO could retard disease progression to chronic renal failure (16 -18) by anemia correction (19) , proangiogenic properties (20 -22) , reduction of oxidative stress (23) , and antiapoptotic effects (24 -26) . However, it is unknown whether the beneficial effects of rhEPO in chronic renal diseases are related to the inhibition of EMT. In this study we hypothesized that renoprotective effect of rhEPO could also be mediated by attenuation of EMT. There-fore, we aimed to examine whether (1) rhEPO treatment has inhibitory effects against progression of renal fibrosis in obstructed kidneys in an animal model of complete unilateral ureteral obstruction (UUO) in vivo and (2) rhEPO treatment has inhibitory effects against TGF-␤1-induced EMT in MDCK cells in vitro. Moreover, (3) we examined whether the inhibitory effects of rhEPO against TGF-␤1-induced EMT in MDCK cells are mediated by changing Smad-2, Smad-3, or phosphorylated Smad-2 expression, which have been demonstrated to be the major signal pathways in TGF-␤1-induced EMT (27, 28) .
Materials and Methods

Experimental Animals
The animal protocols for this study were approved by the boards of the Kyungpook National University and Kyungpook National University Hospital. Male BALB/c mice (Samtako, Osan, Korea) that weighed 20 to 25 g had free access to standard food and water. After an intraperitoneal injection of pentobarbital sodium (50 mg/kg), UUO was made by ligation of the left ureter with 4-0 silk through a left flank incision. A control group of mice were subjected to sham operations that were identical to the ones done for the mice with UUO except that the ureters were not ligated.
Experimental Protocols for UUO
Protocol 1. For determination of the starting time point of rhEPO treatment after the induction of UUO, UUO mice (n ϭ 6) and shamoperated control mice (n ϭ 6) were killed at day 3 or at day 14 after operation, and the changes of expressions of TGF-␤1 and ␣-smooth muscle actin (␣-SMA) were examined (see the Results section). In addition, renal fibrosis in the obstructed kidneys was observed by histopathology and Masson's trichrome staining.
Protocol 2. Five groups of mice (n ϭ 31) were made. Group 1 and group 2 were the sham-operated mice (n ϭ 5) and the UUO mice (n ϭ 5), respectively. An additional 21 mice were subjected to UUO, and 3 d after UUO all mice were randomly assigned to either the rhEPO-treated (CJ Corp., Seoul, Korea) groups (groups 3 and 4) or the vehicle-treated group (group 5; rhEPO solvent; CJ Corp.). For rhEPO treatment, 100 U/kg body wt rhEPO for group 3 (UUOϩE100; n ϭ 7) or 1000 U/kg body wt rhEPO for group 4 (UUOϩE1000; n ϭ 7) was administered intraperitoneally every other day from day 3 to day 14 after UUO. In group 5 (n ϭ 7), vehicle was administered intraperitoneally in a manner identical to the rhEPO treatment. All mice were killed at day 14 under enflurane (Choongwae Pharma Corp., Seoul, Korea) anesthesia.
Semiquantitative Assessment of Renal Fibrosis
Kidney sections (3-m thickness) were stained with Masson's trichrome for light microscopic examination. The fibrotic area was assessed by scoring semiquantitatively as viewed from a light microscope using ϫ20 flat-field objective on the randomly selected four different regions on each section. The Image Acquisition and Analysis Software LabWorks (Ultra-Violet Products Ltd., Cambridge, UK) was used for the analysis.
Immunohistochemistry
Kidney tissues from each experimental group were immersion-fixed with 4% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4) for 2 h. The immunolabeling was performed on the sections from paraffinembedded preparation (3-m thickness) using methods described previously in detail (29, 30) . The sections were incubated overnight at 4°C with primary antibodies against TGF-␤1 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA), ␣-SMA (1:1000; Sigma, St. Louis, MO), or fibronectin (1:3000; BD Biosciences, Bedford, UK). For immunofluorescence staining, the sections were incubated overnight at 4°C with primary antibodies against E-cadherin (1:200; BD Biosciences) or laminin (1:300; Sigma). The immunolabeling was examined by a Zeiss light microscope (Axioplan 2 imaging; Carl Zeiss, Jena, Germany) or a Leica DM IRB inverted microscope (Leica Microsystems, Wetzlar, Germany) equipped with a CoolSNAP HQ camera (Photometrics, Tucson, AZ).
Electron Microscopy
The kidney tissues from each experimental group were fixed in 2% glutaraldehyde in sodium phosphate buffer (pH 7.4) for 2 h, and then they were rinsed in sodium phosphate buffer, postfixed in 1% osmium tetroxide for 1 h, dehydrated in a series of graded ethanol solutions, and then embedded in an Epon mixture. Ultrathin sections (90 nm) were stained with uranyl acetate and lead citrate. The specimens were examined with a Hitachi H-7000 transmission electron microscope (Hitachi, Tokyo, Japan).
Determination of Tissue TGF-␤1 Levels by ELISA
Kidney tissues were homogenized and centrifuged at 4000 ϫ g for 15 min at 4°C. The TGF-␤1 level of the kidney tissue was determined by using the commercial Quantikine TGF-␤1 ELISA kit (R&D Systems, Minneapolis, MN). The concentration of TGF-␤1 in the kidneys was expressed as picograms per milligram of total protein.
Electrophoresis and Immunoblotting
Tissue samples were processed for protein samples using the 4000 ϫ g supernatant of the whole-kidney homogenate (30) . Immunoblotting was done with primary antibodies (see the Immunohistochemistry section). The sites of the antigen-antibody reaction were visualized with using horseradish peroxidase-conjugated secondary antibodies (P447 or P448, diluted 1:3000; Dako, Glostup, Denmark) with an enhanced chemiluminescence (ECL) system and by exposure to photographic film (Hyperfilm ECL, RPN3103K; Amersham Pharmacia Biotech, Little Chalfont, UK). The band densities were quantified by computer scanning of films. We used Scion Image (Scion, Frederick, MD) for computer analysis of band pixel intensities.
MDCK Cell Culture
Because previous studies have used MDCK cells for studying EMT (31, 32) and in our preliminary study we found that strong labeling of EPO receptor was associated with plasma membrane of MDCK cells, we used MDCK cells for studying the direct effects of rhEPO on the TGF-␤1-induced EMT. MDCK cells were cultured at 37°C in 5% CO 2 in DMEM that was supplemented with 10% FBS, penicillin G (100 U/ml), and streptomycin (100 l/ml). The MDCK cells were seeded on sixwell culture plates for 48 h in complete medium that contained 10% FBS. Thereafter, the cells were kept in serum-free medium for 24 h and were placed into the 1% FBS-added medium for 48 h or were treated with recombinant human TGF-␤1 (R&D Systems) at the concentration of 5 ng/ml in 1% FBS-added medium for 48 h. Thereafter, the medium was changed and the cells that were treated with TGF-␤1 were continuously treated with (1) TGF-␤1 (5 ng/ml), (2) 1% FBS-added medium, or (3) TGF-␤1 (5 ng/ml) ϩ 10 U/ml rhEPO for an additional 48 h.
Immunocytochemistry
MDCK cells were grown on chamber slides and were fixed with 3.7% paraformaldehyde in PBS for 30 min. After washing with PBS, cells were permeated with 0.3% Triton for 15 min and were incubated with primary antibodies against ␣-SMA (1:2000; Sigma), vimentin (1:3000; Santa Cruz Biotechnology), zona occludens-1 (ZO-1; 1:500; Santa Cruz Biotechnology), and E-cadherin (1:2000; BD Biosciences) overnight at 4°C. After washing, they were incubated with the secondary antibodies (Alexa Fluor 488 and/or Alexa Fluor 594) for 2 h at room temperature.
Immunoblotting of Smad-2, Smad-2/3, and Phosphorylated Smad-2 in TGF-␤1-or TGF-␤1ϩrhEPO-Co-Treated MDCK Cells
MDCK cells were seeded on six-well culture plates in complete medium that contained 10% FBS for 24 h. Thereafter, the cells were kept in serum-free medium for another 24 h. Cells were treated with TGF-␤1 (5 ng/ml) for 1 h and were followed either by TGF-␤1 (5 ng/ml) treatment or by TGF-␤1 (5 ng/ml) ϩ rhEPO (100 U/ml) co-treatment for an additional 1 h. Cells were harvested, and immunoblotting using whole-cell lysate was done with primary antibodies against Smad-2 (1:1000; Cell Signaling), Smad-2/3 (1:1000; BD Biosciences, Beverly, MA), or phosphorylated-Smad-2 (Ser 465/467 of human Smad-2, 1:1000; Upstate, Lake Placid, NY).
Statistical Analyses
Data are expressed as means Ϯ SE. Statistical analysis of data were performed by using SigmaStat software (Jandel Scientific, San Rafael, CA). Comparison among groups was made with one-way ANOVA, and this was followed by the Student-Newman-Keuls test. Multiple- comparisons tests were applied only when a significant difference was determined on the ANOVA (P Ͻ 0.05). P Ͻ 0.05 was considered statistically significant.
Results
Expressions of TGF-␤1 and ␣-SMA Were Increased in UUO Kidneys (Protocol 1)
In protocol 1, we examined the changes in the expressions of TGF-␤1 and ␣-SMA in the obstructed kidneys at day 3 ( Figure  1, A, B , E, and F) and day 14 ( Figure 1, C, D, G, and H) after UUO. Immunoperoxidase microscopy demonstrated increased labeling intensity of TGF-␤1 ( Figure 1B ) and ␣-SMA ( Figure 1F ) at the interstitial area in the obstructed kidneys compared with the sham-operated control kidneys at day 3 after UUO. The labeling intensity was more pronounced at day 14 ( Figure 1 , D and H). ELISA also revealed significantly increased TGF-␤1 levels in the obstructed kidneys at day 3 (46.0 Ϯ 5.6 versus 20.0 Ϯ 1.9 pg/mg protein; P Ͻ 0.05) and day 14 (113.0 Ϯ 11.3 versus 23.5 Ϯ 1.6 pg/mg protein; P Ͻ 0.05) compared with the corresponding sham-operated controls. Moreover, renal fibrosis was demonstrated by the Masson's trichrome staining for collagen in the obstructed kidneys at day 3 (data not shown). This indicated that UUO is associated with renal interstitial fibrosis, even in the early phase, which was observed at day 3 after UUO. Thus, in the protocol 2, rhEPO treatment was initiated from day 3 after UUO to examine whether rhEPO treatment can affect the expressions of TGF-␤1 and ␣-SMA and attenuate the renal interstitial fibrosis in response to UUO.
rhEPO Treatment Attenuated Progressive Fibrosis in UUO Kidneys (Protocol 2)
UUO induced an increase of collagen on the Masson's trichrome-stained kidney sections ( Figure 2B ) at day 14 compared with the control (Figure 2A ). In contrast, collagen was reduced in the rhEPO-treated UUO kidneys ( Figure 2 , C and D), compared with the untreated (Figure 2B ) or the vehicletreated UUO kidneys ( Figure 2E ). This was also demonstrated by semiquantitative assessment of the fibrotic area on the Masson's trichrome-stained sections of renal tissue ( Figure 2F ).
rhEPO Treatment Attenuated Increase of TGF-␤1 in UUO Kidneys (Protocol 2)
Strong immunoperoxidase labeling of TGF-␤1 was seen at the interstitium of the untreated or the vehicle-treated UUO kidneys at day 14 ( Figure 3 , B and E). In contrast, rhEPO treatment (both UUOϩE100 and UUOϩE1000) was associated with decreased labeling of TGF-␤1 (Figure 3, C and D) . ELISA also revealed markedly increased TGF-␤1 levels in the untreated or the vehicle-treated UUO kidneys. In contrast, rhEPO treatment (both UUOϩE100 and UUOϩE1000) significantly decreased the TGF-␤1 levels in the obstructed kidneys ( Figure 3F ).
rhEPO Treatment Attenuated Increased Expressions of ␣-SMA and Fibronectin and the Decreased Expressions of E-cadherin and Laminin in UUO Kidneys (Protocol 2)
Control kidneys revealed no or very weak labeling of ␣-SMA ( Figure 4A ) and fibronectin ( Figure 4F ) in the renal interstitium, whereas the labeling of ␣-SMA and fibronectin was prominent in the untreated (Figure 4 , B and G) or the vehicle-treated UUO kidneys ( Figure 4 , E and J) at day 14. In the control kidney, strong labeling of the E-cadherin was associated with basolateral plasma membrane of the cortical collecting duct cells and the distal convoluted tubule cells in kidney cortex ( Figure 4K ). Less intense labeling was also seen in the proximal tubule cells. In contrast, UUO kidneys ( Figure 4L ) revealed decreased labeling intensity of E-cadherin in the cortical collecting duct cells, the distal convoluted cells, and the proximal tubule cells. For the laminin staining ( Figure 4 , P through T), decreased laminin labeling was noted in the tubules of the untreated ( Figure 4Q ) or the vehicle-treated ( Figure 4T ) UUO kidneys. Next, we examined the effects of rhEPO treatment in mice with UUO. Importantly, the rhEPO treatment (both UUOϩE100 and UUOϩE1000) attenuated the increased labeling intensity of ␣-SMA (Figure 4 , C and D) and fibronectin ( Figure 4 , H and I) in the obstructed kidneys. Moreover, E-cadherin ( Figure 4 , M and N) and laminin ( Figure 4 , R and S) expression was maintained in response to rhEPO treatment; therefore, the disruption of tubular basement membrane might be ameliorated with rhEPO treatment. This observation could indicate that rhEPO treatment inhibits the process of EMT in the obstructed kidneys, which is characterized by the loss of epithelial phenotype, gain of mesenchymal phenotype, and disruption of tubular basement membrane.
Consistent with the immunohistochemistry, immunoblot analysis revealed the increased ␣-SMA and the decreased E-cadherin expression in the obstructed kidneys of the untreated or the vehicle-treated UUO mice compared with the controls ( Figure 5 ). In contrast, rhEPO treatment (UUOϩ E100 and UUOϩE1000) significantly inhibited the upregulation of the ␣-SMA ( Figure 5, A and B ). E-cadherin expression was not reversed in the UUO group that was treated with lower dosage of rhEPO (UUOϩE100), whereas the higher dosage of rhEPO treatment (UUOϩE1000) significantly in- Figure 4 . Immunoperoxidase labeling of ␣-SMA (A through E) and fibronectin (F through J) and immunofluorescent labeling of E-cadherin (K through O) and laminin (P through T) in protocol 2. Increased labeling of ␣-SMA and fibronectin at the interstitium was observed in UUO (B and G), which was decreased by rhEPO treatment (C and D, H and I). The E-cadherin labeling intensity was decreased in the UUO (L) and vehicle-treated UUO groups (O), whereas the labeling was maintained in the rhEPO-treated groups (M and N). The laminin labeling intensity was decreased in the UUO (Q) and vehicle-treated UUO groups (T), whereas their labeling intensity was maintained by rhEPO treatment (R and S). CD, cortical collecting duct; DT, distal convoluted tubule.
hibited the downregulation of E-cadherin ( Figure 5 , A and C) compared with the untreated or the vehicle-treated UUO mice.
rhEPO Treatment Attenuated Structural Changes Induced by UUO: Examination by Electron Microscope (Protocol 2)
We observed the structural changes of the obstructed kidneys in UUO mice by electron microscopic examination. The control kidneys showed well-preserved tubular epithelial cells exhibiting abundant mitochondria and surrounding thin basement membrane ( Figure 6A, arrows) , whereas the obstructed kidneys showed irregularly wrinkled basement membranes ( Figure 6B , arrows) and swelling of the epithelial cells. The intertubular area of the UUO kidneys was expanded in a fibrotic matrix with fibroblast-like cells ( Figure 6B, asterisk) , and the capillaries were collapsed. We also noted damaged intracellular organelles and autophagic vacuoles in the intertubular areas of the UUO kidneys. These structural changes were ameliorated by rhEPO treatment (Figure 6, C and D) . The kidney tissues from the mice that were treated with the lower dosage of rhEPO (UUOϩE100; Figure 6C ) were associated with a decreased number of fibroblast-like cells ( Figure 6C , asterisk) and opened capillaries with endothelial cells in the intertubular area. The surrounding epithelial cells had less wrinkled basement membrane ( Figure 6C; arrows) . Moreover, the kidney tissues from the mice that were treated with the higher dosage of rhEPO (UUOϩE1000; Figure 6D ) showed nearly normallooking tubular epithelial cells with focally wrinkled basement membranes ( Figure 6D, arrows) . The expansion of the intertubular area was not obvious, and only a few fibroblast-like cells were present ( Figure 6D, asterisk) . The vehicle-treated UUO mice ( Figure 6E ) showed structural changes that were similar to those of the untreated UUO mice.
rhEPO Treatment Attenuated TGF-␤-Induced EMT in MDCK Cells
Because TGF-␤1 is the main inducer of the EMT (5,27), we incubated the MDCK cells with 5 ng/ml TGF-␤1 for 48 h to induce EMT. Morphologically, MDCK cells were changed from a cuboidal shape to a spindle shape in response to the TGF-␤1, whereas rhEPO co-treatment with TGF-␤1 reversed the TGF-␤1-induced changes of cellular morphology (data not shown).
The changes of cellular morphology were accompanied by increased labeling intensity of ␣-SMA (Figure 7 , B and C) and vimentin ( Figure 7 , H and I) after TGF-␤1 treatment. Importantly, the increased labeling intensity of ␣-SMA and vimentin after TGF-␤1 treatment was reduced by rhEPO treatment (Figure 7 , E and F, K and L). Although the reduction of labeling intensity was more prominent in response to rhEPO treatment after removal of TGF-␤1 stimulation ( Figure 7 , E and K), the effects of rhEPO were also evident in the presence of continuous TGF-␤1 stimulation ( Figure 7, F and L) . In contrast, the decreased expressions of ZO-1 ( Figure 7 , N and O) and E-cadherin ( Figure 7 , T and U) after TGF-␤1 treatment were reversed by the rhEPO treatment ( Figure 7 , Q and R, W and X). Consistent with these findings, immunoblots revealed upregulation of ␣-SMA expression when the cells were exposed to TGF-␤1, whereas rhEPO treatment significantly attenuated the TGF-␤1-induced upregulation of ␣-SMA (Figure 8, A and B) . The decreased E-cadherin expression after TGF-␤1 exposure was significantly reversed by rhEPO treatment (Figure 8, A and C) . However, reduction of ␣-SMA expression was not obvious in the TTE group (TGF-␤1 exposure followed by TGF-␤1ϩrhEPO), whereas the change of E-cadherin expression was significant in both rhEPO-treated groups (TE [TGF-␤1 exposure followed by rhEPO treatment without TGF-␤1 exposure] and TTE), compared with TGF-␤1 exposure followed by fresh media.
rhEPO Treatment Attenuated TGF-␤1-Induced Upregulation of Smad-2 Phosphorylation in MDCK Cells
As a mechanistic experiment for the effects of rhEPO, we examined whether the rhEPO treatment affected Smad signaling, which has been known to play a major role in the process of TGF-␤1-induced EMT (27, 33) . In Figure 9 , the cells that were treated with TGF-␤1 for 1 h followed by the subsequent TGF-␤1 treatment for an additional 1 h (TT) showed unchanged expression of Smad-2/3 and Smad-2 (data not shown), but the expression of phosphorylated Smad-2 expression was significantly increased in the TT when compared with the cells that were treated with TGF-␤1 for 1 h followed by the subsequent co-treatment of TGF-␤1ϩrhEPO treatment for additional 1 h (TTE; Figure 9 ). Thus, it could indicate that rhEPO has inhibitory effects against TGF-␤1-induced EMT, at least partly by attenuating the TGF-␤1-induced upregulation of phosphorylated Smad-2.
Discussion
Although any specific therapies that inhibit the progression of chronic renal disease are unavailable, preventing or inhibiting EMT would be one therapeutic option that potentially inhibits renal fibrosis. In this study, we demonstrated that rhEPO was able to retard TGF-␤1 expression in the obstructed kidneys and the progression of renal fibrosis in mice with complete UUO. Moreover, rhEPO attenuated the TGF-␤1-induced EMT in MDCK cells, and this could be mediated by attenuation of the TGF-␤1-induced upregulation of phosphorylated Smad-2. Therefore, in addition to its use for correcting anemia, our findings suggest that rhEPO treatment could be applied to inhibit the process toward renal fibrosis, at least partly, by attenuating EMT. 
Upregulation of TGF-␤1 Expression in UUO Kidneys Associated with Loss of Epithelial Phenotype and Acquisition of Mesenchymal Phenotype
For studying the antifibrotic effect of rhEPO, we used the UUO mouse model to induce renal fibrosis. We demonstrated that UUO induced an increase of TGF-␤1 expression in the renal tissue.
Because TGF-␤1 is known to be a major regulator of EMT induction, the increased expression of TGF-␤1 in the obstructed kidneys could be involved in the loss of the epithelial phenotype and the acquisition of the mesenchymal phenotype. Immunohistochemistry revealed that expression of the epithelial cell phenotype marker (E-cadherin) in the obstructed kidneys was reduced after Figure 7 . Immunofluorescent microscopy of ␣-SMA (A through F), vimentin (G through L), zona occludens-1 (ZO-1) (M through R), and E-cadherin (S through X) in MDCK cells after TGF-␤1 and rhEPO treatment. The increased immunolabeling intensity of ␣-SMA (B and C, red) and vimentin (H and I, green) that was seen in response to TGF-␤1 treatment was decreased by rhEPO treatment (E and F, K and L). In contrast, the decreased immunolabeling intensity of ZO-1 (N and O, green) and E-cadherin (T and U, red) in response to TGF-␤1 treatment was reversed by rhEPO treatment (Q and R, W and X). The blue staining (A through X) is nuclear counterstaining with DAPI. MM, cells were exposed to medium for 48 h and then to the fresh medium for subsequent 48 h; TT, cells were exposed to TGF-␤1-containing medium for 48 h and then to another TGF-␤1-containing medium for subsequent 48 h; TM, cells were exposed to TGF-␤1-containing medium for 48 h and then to fresh medium for subsequent 48 h; ME, cells were exposed to medium for 48 h and then to rhEPO-containing medium for subsequent 48 h; TE, cells were exposed to TGF-␤1-containing medium for 48 h and then to rhEPO-containing medium for subsequent 48 h; TTE, cells were exposed to TGF-␤1-containing medium for 48 h and then to medium that contained both TGF-␤1 and rhEPO for subsequent 48 h.
UUO, whereas expression of mesenchymal cell phenotype markers (␣-SMA and fibronectin) was increased. In addition to these changes, disruption of the tubular basement membrane was observed, as revealed by immunostaining of laminin, which is one of the components of tubular basement membrane, and by electron microscopic examination. Electron microscopy revealed that the intertubular area of the UUO kidney was expanded with fibroblast-like cells in the fibrotic matrix. Some of the fibroblast-like cells in the interstitium of the UUO kidney had the features of epithelial cells that were characterized by numerous mitochondria in the cytoplasm. These findings suggest that during the process of renal fibrosis, epithelial cells could be transdifferentiated into interstitial fibroblasts, and this is accompanied by disruption of the tubular basement membrane as previously demonstrated (1,2), although we cannot exclude a possibility that the increased expression of ␣-SMA in UUO kidneys could also be induced by resident fibroblasts in addition to the myofibroblasts from EMT. Consistent with this, previous studies with different animal models of chronic renal disease have reported that EMT of the renal tubular epithelial cells was associated with progressive fibrosis (1,3) , although a recent study also suggested that renal progenitor tubular cells might be a cell population that proliferates, migrates, Immunoblotting analyses for phosphorylated Smad-2 (p-Smad-2) and Smad-2/3 in MDCK cells after TGF-␤1 and rhEPO treatment. (A) Cells that were treated with TGF-␤1 for 1 h followed by the additional TGF-␤1 treatment for 1 h (TT) showed unchanged Smad-2/3 expression, whereas p-Smad-2 expression was significantly increased compared with the cells that were treated with TGF-␤1 for 1 h followed by the co-treatment of TGF-␤1ϩrhEPO for an additional 1 h (TTE). Densitometric analysis of two independent experiments (B and C). The data were normalized by the density of ␤-actin control. *P Ͻ 0.05 versus TT.
and transdifferentiates into fibroblast-like cells during renal fibrosis (34) .
rhEPO Treatment Demonstrated Renoprotective Effects in UUO Mice In Vivo and Inhibited TGF-␤-Induced EMT in MDCK Cells In Vitro
We demonstrated that rhEPO treatment decreased the expression of TGF-␤1 in the obstructed kidneys, and it subsequently attenuated the expression of ␣-SMA and restored the expression of E-cadherin. The UUO-induced disruption of the basement membrane was also ameliorated by rhEPO treatment. The protective effects of rhEPO in vivo were also observed by the in vitro experiment, which showed that co-treatment of TGF-␤1 with rhEPO inhibited the TGF-␤1-induced EMT in MDCK cells. In contrast, withdrawal of TGF-␤1 alone decreased the upregulated ␣-SMA expression, but it did not normalize the downregulated E-cadherin expression, indicating that the co-treatment of rhEPO could inhibit more effectively the TGF-␤1-induced EMT. It should be emphasized that in vivo EMT occurs primarily in the proximal tubule, whereas MDCK cells, which we used for the in vitro study, are of distal tubular origin. Therefore, it is unclear whether all of the observed effects of rhEPO against TGF-␤1-induced EMT in MDCK cells (e.g., distal tubule) in this study could occur identically in the proximal tubule cell lines or in the proximal tubules in vivo. However, as shown in Figure 4 , immunolabeling intensity of E-cadherin and laminin in the proximal tubule of the kidney cortex was fairly maintained in response to rhEPO treatment in UUO compared with the untreated UUO. Moreover, immunolabeling intensity of ␣-SMA and fibronectin in the renal interstitium around the proximal tubules was much weaker after rhEPO treatment. These findings may suggest that rhEPO is likely to be effective in attenuating EMT in the proximal tubule as well, although we did not examine the effects of rhEPO directly on the proximal tubule cell lines in vitro.
Potential Mechanisms of rhEPO Treatment in Reversing TGF-␤1-Induced EMT
The mechanism of how rhEPO inhibits TGF-␤1-induced EMT is unknown. Multiple intracellular signaling pathways have been suggested to mediate EMT. TGF-␤1 is probably the key inducer of EMT (3, 5, 35) because TGF-␤1 signaling is sufficient to induce EMT in cultured epithelial cells (35) . Whereas TGF-␤1 responses are initiated by the interaction of TGF-␤1 with cell surface receptors, the intracellular signaling pathways that are involved in EMT are still incompletely understood. Li et al. (27) showed that TGF-␤1 induces Smad-2 phosphorylation in a normal rat tubular epithelial cell line, NRK-52E, and results in the transformation of epithelial cell into myofibroblast phenotype with the loss of E-cadherin and de novo expression of ␣-SMA and collagens. Moreover, because it has been demonstrated that Smad-3 is the essential mediator of TGF-␤1 signaling and important in TGF-␤1-induced fibrosis (36), we examined whether rhEPO treatment on the MDCK cells in the presence of TGF-␤1 affected the expression of Smad-2, Smad-3, and phosphorylated Smad-2 levels.
As shown in Figure 9 , TGF-␤1 treatment increased the expression of phosphorylated Smad-2 in MDCK cells, whereas rhEPO co-treatment in the presence of TGF-␤1 decreased the expression of phosphorylated Smad-2. In contrast, TGF-␤1 treatment with or without rhEPO did not change the expression of Smad-2 and Smad-2/3. This may indicate that rhEPO is likely to counteract TGF-␤1-induced EMT, at least partly, by decreasing Smad-2 phosphorylation but not by altering the expression of Smad-2 and Smad-3. Besides Smad signaling, TGF-␤1 can activate other signal transduction pathways in the renal epithelial cells, including p38 mitogen-activated protein kinase, Akt/protein kinase B, Rho A, and ␤-catenin (37, 38) . Further studies are therefore warranted to understand the underlying mechanism of the rhEPO in attenuating EMT, in addition to phosphorylated Smad-2.
Conclusion
We demonstrated that rhEPO has an inhibitory effect against the progression of renal fibrosis by decreasing TGF-␤1 expression in the UUO kidneys of mice. Moreover, rhEPO directly attenuated TGF-␤1-induced EMT in MDCK cells. rhEPO is likely to counteract TGF-␤1-induced EMT, at least partly, by decreasing Smad-2 phosphorylation. These results suggest that one of the possible mechanisms of rhEPO's renoprotective effect could be mediated by the inhibition of TGF-␤1-induced EMT.
